CeMM is a biomedical flagship institute in the heart of Europe, Vienna. We are committed to highest scientific standards and provide an international environment representing approximately 45 nationalities. The working language is English. CeMM has been ranked by The Scientist as one of the Best Places to Work Academia worldwide (link: http://goo.gl/51VMO). In the past 3 years CeMM groups published numerous ground-breaking studies in prestigious journals such as Science, Cell, Nature, New England Journal of Medicine, Nature Immunology, Immunity etc. CeMM is located within the medical campus of Vienna and operates several technology platforms (chemical biological screening, proteomics, metabolomics, next-generation sequencing) as well as extensive bioinformatics infrastructure.
The Winter laboratory is working at the interface of chemical biology, cancer and gene-control with a particular focus on targeted protein degradation. The ERC-funded project “Glue2Degrade” aims to write the next chapter in the field of targeted protein degradation by systematically identifying and characterizing small “molecular glue”-type E3 ligase modulators. The ultimate goal of the Winter lab is to develop chemical strategies that allow the targeted degradation of oncogenic transcription factors. Dr. Winter’s seminal paper, showcasing the first in vivo compatible and generalizable strategy for targeted protein degradation (Winter et al., Science 2015), has sparked an immense research interest in the field. Since establishing his independent research lab at CeMM, the lab published, among others, molecules for the homolog-selective degradation of CDK6 (Brand et al., Cell Chemical Biology 2019), and a general survey for potential resistance mechanisms to small molecule degraders (Mayor-Ruiz et al., Molecular Cell 2019). The lab closely collaborates with the Platform Austria for Chemical Biology PLACEBO, a unique chemical screening infrastructure with a collection of 90,000 small molecule compounds. In addition, we apply proteomics, chemistry, mass spectrometry, bioinformatics, and next generation sequencing to address our research questions. In this position you will have the opportunity to work in an innovative research environment and collaborate closely with other groups at CeMM.
The Winter laboratory at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, is recruiting a synthetic organic chemist to develop novel strategies for the treatment of cancer by chemically reprogramming the cellular degradation machinery.